LY96 and Sepsis: Some studies have demonstrated the importance of timing in the use of TLR inhibitors in sepsis.[39, 40] One study found that the time of administration of 5E3, a TLR4/MD‐2 inhibitory antibody, influences survival rates in mice.[39] Protection was observed when 5E3 was administered up to 4 h before or after an LPS challenge, but it had no effect when administered 8 h post‐challenge.